Update in inclusion body myositis

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 763-771

  Machado, Pedro ^a   Brady, Stefen ^a   Hanna, Michael G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnosis; Inclusion body myositis; Myopathies; Pathogenesis; Treatment

Indexed keywords

5 NUCLEOTIDASE 1A; 5' NUCLEOTIDASE; ARIMOCLOMOL; AUTOANTIBODY; BIOLOGICAL MARKER; BRCA1 PROTEIN; ETANERCEPT; FOLLISTATIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN; LITHIUM; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PITTSBURGH COMPOUND B; PROTEIN P62; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; AUTOIMMUNITY; AUTOPHAGY; DERMATOMYOSITIS; DISEASE COURSE; EARLY DIAGNOSIS; ENDOPLASMIC RETICULUM STRESS; EVIDENCE BASED PRACTICE; GASTROCNEMIUS MUSCLE; GENE TRANSFER; HEAT SHOCK RESPONSE; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE BIOPSY; MUSCLE MASS; MUSCLE STRENGTH; MYOSITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

5'-NUCLEOTIDASE; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; MYOSITIS, INCLUSION BODY;

EID: 84885201889     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434671.77891.9a     Document Type: Review

References (61)

1. Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15:1350-1353
2. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79:1056-1060
3. Benveniste O, Guiguet M, Freebody J, et al. Long-Term observational study of sporadic inclusion body myositis. Brain 2011; 134 (Pt 11): 3176-3184
4. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713
5. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: Observations in 40 patients. Brain 1989; 112 (Pt 3):727-747
6. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: Analysis of 32 cases. J Rheumatol 1992; 19:1385-1389
7. Vershuuren JJ, van Engelen BGM, van der Hoeven J, Hoogendijk J. Diagnostic criteria for neuromuscular disorders. 2nd ed. London: Royal Society of Medicine Press; 1997
8. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996; 40:581-586
9. Inclusion body myositis. 188th European Neuromuscular Centre Workshop; (Organiser: Mike Rose). Full report to be published in Neuromuscular Disorders, 2nd to 4th December 2011, Naarden, the Netherlands
10. Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010; 20:414-421
11. Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20:142-147
12. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6:e20266
13. .Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 50-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408-418
14. .Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 50-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73:397-407
15. Allenbach Y, Benveniste O, Decostre V, et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 2012; 22:980-986
16. .Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials. Neuromuscul Disord 2013; 23:404-412
17. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: An end stage with major disabilities. Brain 2011; 134 (Pt 11): 3167-3175
18. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132 (Pt 6): 1536-1544
19. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: Clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89:123-131
20. Rose MR, McDermott MP, Thornton CA, et al. A prospective natural history study of inclusion body myositis: Implications for clinical trials. Neurology 2001; 57:548-550
21. Lowes LP, Alfano L, Viollet L, et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012; 45:163-168
22. Jackson CE, Barohn RJ, Gronseth G, et al. Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity. Muscle Nerve 2008; 37:473-476
23. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158:1453-1455
24. Carpenter S, Karpati G, Wolfe L. Virus-like filaments and phospholipid accumulation in skeletal muscle: Study of a histochemically distinct chronic myopathy. Neurology 1970; 20:889-903
25. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis: Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48:1229-1234
26. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008; 64:15-24
27. Greenberg SA. How citation distortions create unfounded authority: Analysis of a citation network. BMJ 2009; 339:b2680
28. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70:418-424
29. Weihl CC, Pestronk A. Sporadic inclusion body myositis: Possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010; 23:482-488
30. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406-416
31. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18:27-33
32. Nalbantoglu J, KarpatiG, Carpenter S. Conspicuous accumulation of a singlestranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144:874-882
33. Olive M, Janue A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262-273
34. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19-31
35. Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 2008; 105:3785-3789
36. Kusters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009; 117:209-211
37. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189
38. Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009; 118:407-413
39. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 2007; 462:245-253
40. Bjorkoy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-614
41. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/ LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-24145
42. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009; 278:25-29
43. D'Agostino C, Nogalska A, Cacciottolo M, et al. Abnormalities of NBR1, a novel autophagy-Associated protein, in muscle fibers of sporadic inclusionbody myositis. Acta Neuropathol 2011; 122:627-636
44. Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 1987; 30:397-403
45. Needham M, Mastaglia FL. Inclusion body myositis: Current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6:620-631
46. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 2000; 55:1385-1387
47. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013. [Epub ahead of print]
48. Del Grande F, Carrino JA, Del Grande M, et al. Magnetic resonance imaging of inflammatory myopathies. Top Magn Reson Imaging 2011; 22:39-43
49. Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010; 20:2447-2460
50. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50:1153-1161
51. Garcia J. MRI in inflammatory myopathies. Skeletal Radiol 2000; 29:425-438
52. Maetzler W, Reimold M, Schittenhelm J, et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry 2011; 82:1060-1062
53. .Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013; 15:329
54. Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-Term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: A retrospective study of 16 patients. Clin Exp Rheumatol 2012; 30:838-842
55. .Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012; 24:201-207
56. Efficacy of aerobic training of people with neuromuscular diseases: A randomised cross-over study. http://www.controlled-Trials.com/ISRCTN 99826269. [Accessed 2 May 2013]
57. Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: A randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial. Ann Rheum Dis 2013; 72 (Suppl 3):164
58. Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis. http://www.clinicaltrials.gov/ct2/show/NCT01423110. [Accessed 2 May 2013]
59. Follistatin gene transfer to patients with becker muscular dystrophy and sporadic inclusion body myositis. http://www.clinicaltrials.gov/ct2/show/ NCT01519349. [Accessed 2 May 2013]
60. Double-blind, randomized, placebo-controlled trial of etanercept for 12 months in subjects with inclusion body myositis. http://www.clinicaltrials. gov/ct2/show/NCT00802815. [Accessed 2 May 2013]
61. Lithium in inclusion body myositis (IBM) (Li-IBM). http://www. clinicaltrials. gov/ct2/show/NCT00917956. [Accessed 2 May 2013]